Prestige BioPharma Statistics

Total Valuation

KRX:950210 has a market cap or net worth of KRW 178.00 billion. The enterprise value is 213.14 billion.

Market Cap	178.00B
Enterprise Value	213.14B

Important Dates

The next estimated earnings date is Friday, May 30, 2025.

Earnings Date	May 30, 2025
Ex-Dividend Date	n/a

Share Statistics

KRX:950210 has 12.02 million shares outstanding. The number of shares has decreased by -0.07% in one year.

Current Share Class	n/a
Shares Outstanding	12.02M
Shares Change (YoY)	-0.07%
Shares Change (QoQ)	-0.13%
Owned by Insiders (%)	30.40%
Owned by Institutions (%)	0.09%
Float	3.59M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	30.33
PB Ratio	0.36
P/TBV Ratio	0.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-7.14
EV / Sales	36.32
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.34

Financial Position

The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.35.

Current Ratio	1.47
Quick Ratio	1.35
Debt / Equity	0.35
Debt / EBITDA	n/a
Debt / FCF	-1.92
Interest Coverage	-8.52

Financial Efficiency

Return on equity (ROE) is -11.71% and return on invested capital (ROIC) is -6.11%.

Return on Equity (ROE)	-11.71%
Return on Assets (ROA)	-5.41%
Return on Invested Capital (ROIC)	-6.11%
Return on Capital Employed (ROCE)	-11.01%
Revenue Per Employee	108.69M
Profits Per Employee	-552.84M
Employee Count	54
Asset Turnover	0.01
Inventory Turnover	0.09

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +82.58% in the last 52 weeks. The beta is 1.13, so KRX:950210's price volatility has been higher than the market average.

Beta (5Y)	1.13
52-Week Price Change	+82.58%
50-Day Moving Average	13,880.00
200-Day Moving Average	14,093.75
Relative Strength Index (RSI)	56.38
Average Volume (20 Days)	143,433

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KRX:950210 had revenue of KRW 5.87 billion and -29.85 billion in losses. Loss per share was -496.51.

Revenue	5.87B
Gross Profit	4.65B
Operating Income	-63.11B
Pretax Income	-58.53B
Net Income	-29.85B
EBITDA	-44.53B
EBIT	-63.11B
Loss Per Share	-496.51

Full Income Statement

Balance Sheet

The company has 242.88 billion in cash and 175.12 billion in debt, giving a net cash position of 67.76 billion or 5,637.44 per share.

Cash & Cash Equivalents	242.88B
Total Debt	175.12B
Net Cash	67.76B
Net Cash Per Share	5,637.44
Equity (Book Value)	493.39B
Book Value Per Share	1,299.58
Working Capital	85.94B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -68.80 billion and capital expenditures -22.20 billion, giving a free cash flow of -91.00 billion.

Operating Cash Flow	-68.80B
Capital Expenditures	-22.20B
Free Cash Flow	-91.00B
FCF Per Share	-7,571.17

Full Cash Flow Statement

Margins

Gross Margin	79.25%
Operating Margin	-1,075.25%
Pretax Margin	-997.26%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

KRX:950210 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.07%
Shareholder Yield	0.07%
Earnings Yield	-16.77%
FCF Yield	-51.12%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KRX:950210 has an Altman Z-Score of -0.43. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.43
Piotroski F-Score	n/a